Structure via PubChem · Public domain (PubChem)
doxercalciferol
Sign in to saveAlso known as 1α-hydroxyvitamin D2, 1αOHD2, 1-α-hydroxyergocalciferol, 1alpha-Hydroxyergocalciferol, 1α-Hydroxyergocalciferol, 1alpha-hydroxyvitamin D2, 1-Hydroxyergocalciferol, (1S,3R,5Z,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraene-1,3-diol
Doxercalciferol (or 1-hydroxyergocalciferol, trade name Hectorol) is drug for secondary hyperparathyroidism and metabolic bone disease. It is a synthetic analog of ergocalciferol (vitamin D2). It suppresses parathyroid synthesis and secretion.
In the Vinony graph
Vinony's link graph records 36 inbound references to doxercalciferol, and connects out to cholecalciferol, ergocalciferol and liver.
It sits within the topics Chembox image size set, Diols and ECHA InfoCard ID from Wikidata.
Vinony links it to 6 Wikipedia language editions.
Chemical data
- Formula
- C28H44O2
- Molecular weight
- 412.6 g/mol
- IUPAC name
- trans-(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
- SMILES
- C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C
- InChIKey
- HKXBNHCUPKIYDM-CGMHZMFXSA-N
- XLogP
- 6.3
- Polar surface area
- 40.5 Ų
- H-bond donors
- 2
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1999
- Admin. routes
- oral, parenteral
- Indications
- psoriasis, neoplasm, chronic kidney disease, parathyroid disease
via ChEMBL · EBI
Research
174 papers- Doxercalciferol alleviates UVB-induced HaCaT cell senescence and skin photoaging.International immunopharmacology · 2024
- Doxercalciferol treatment of secondary hyperparathyroidism.The Annals of pharmacotherapy · 2006
- Pharmacokinetics of vitamin D toxicity.The American journal of clinical nutrition · 2008
- Doxercalciferol Alleviates Bone Deteriorations and Cartilage Degeneration in Aging Mice.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2020
- Doxercalciferol, a pro-hormone of vitamin D, prevents the development of cardiac hypertrophy in rats.Journal of cardiac failure · 2011
via PubMed
Wikidata facts
- Subclass of
- secosteroid
- Mass
- 412.334
- Has use
- medication
Show 6 more facts
- chemical formula
- C₂₈H₄₄O₂
- isomeric SMILES
- C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C
- canonical SMILES
- CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C
- subject has role
- vitamin
- physically interacts with
- vitamin D receptor
- Commons category
- Doxercalciferol
Sources (6)
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Doxercalciferol (or 1-hydroxyergocalciferol, trade name Hectorol) is drug for secondary hyperparathyroidism and metabolic bone disease. It is a synthetic analog of ergocalciferol (vitamin D2). It suppresses parathyroid synthesis and secretion.
Doxercalciferol is the vitamin D2 analogue of alfacalcidol. It undergoes 25-hydroxylation in the liver to become the active ercalcitriol, without the involvement of kidneys.
Excerpted from Wikipedia’s “doxercalciferol” article, available under the CC BY-SA 4.0 licence.